Cagent Vascular’s Serranator PTA Serration Balloon Catheter Offers ATK Product Sizes

June 1, 2022—Cagent Vascular, Inc. announced the commercial launch of the Serranator above-the-knee (ATK) product. An expansion of their current Serranator percutaneous transluminal angioplasty serration balloon catheter offering, this launch includes larger balloons to treat superficial femoral and popliteal arteries in the ATK segment.

According to the company, the Serranator is an angioplasty device with serrated metal strips embedded on a semicompliant balloon. The device’s technology is designed to create multiple longitudinal lines of interrupted microserrations within the luminal surface to aid in arterial expansion. The differentiated mechanism of action results in predictable and controlled lumen gain using low atmospheres of pressure. The company website states that the ATK product sizes include diameters of 4, 5, and 6 mm and lengths of 40 and 120 mm.

In January 2021, Cagent Vascular launched the Serranator device in below-the-knee (BTK) sizes, including 2.5-, 3-, 3.5-mm balloon diameters and 40-, 80-, and 120-mm balloon lengths. The company noted that the device has since been adopted at many targeted centers, including by Dr. Peter Soukas with Miriam Hospital in Providence, Rhode Island, and Dr. Prakash Krishnan with Mount Sinai Hospital in New York, New York.

“I have used the ATK-sized balloons and, in my experience, have been impressed with the acute luminal gain in highly calcified arteries,” said Dr. Soukas in the press release. “The goal for all angioplasty is to create the biggest lumen possible while minimizing dissection. This ideal acute outcome, which I get with the Serranator, will be beneficial in the ATK arteries whether I follow on with a drug-coated balloon or a stent. I see this becoming a regular part of my ATK treatment algorithm.”

Carol A. Burns, CEO of Cagent Vascular, stated, “Expanding into the ATK segment will generate significant incremental revenue and build on our success from last year’s BTK product launch where the Serranator was used as the primary therapy. ATK, we anticipate the Serranator will primarily be used in conjunction with other therapies. With the addition of these expanded sizes, we are excited to enter into an even larger market, enabling physicians to use the Serranator to help more patients.”